# Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

> **NCT01700192** · PHASE3 · COMPLETED · sponsor: **ALK-Abelló A/S** · enrollment: 1482 (actual)

## Conditions studied

- Rhinitis, Allergic, Perennial
- Rhinitis, Allergic, Nonseasonal

## Interventions

- **BIOLOGICAL:** MK-8237 tablets
- **BIOLOGICAL:** Placebo tablets
- **DRUG:** Rescue Medication: Self-Injectable Epinephrine
- **DRUG:** Rescue Medication: Loratadine tablets
- **DRUG:** Rescue Medication: Olopatadine ophthalmic drops
- **DRUG:** Rescue Medication: Mometasone furoate nasal spray

## Key facts

- **NCT ID:** NCT01700192
- **Lead sponsor:** ALK-Abelló A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 1482 (ACTUAL)
- **Last updated:** 2017-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01700192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01700192, "Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01700192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*